Effect of Remote Ischemic Postcondioning on Glymphatic System in Acute Stroke

NCT ID: NCT05305625

Last Updated: 2022-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators aimed to investigate the changes of glymphatic function after remote ischemic postcondioning treatment in acute ischemic stroke .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard therapy

Patients will be treated with Guideline standard

Group Type EXPERIMENTAL

standard therapy

Intervention Type DRUG

received standardized treatment

remote ischemic postcondioning and standard therapy

Patients will be treated with remote ischemic postcondioning and Guideline standard , remote ischemic postcondioning twice a day for a total of 3 days.

Group Type EXPERIMENTAL

remote ischemic postcondioning

Intervention Type PROCEDURE

remote ischemic postcondioning twice daily, for three consecutive days,the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning

standard therapy

Intervention Type DRUG

received standardized treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

remote ischemic postcondioning

remote ischemic postcondioning twice daily, for three consecutive days,the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning

Intervention Type PROCEDURE

standard therapy

received standardized treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient was 18-80 years old;
* The NIHSS score was ≤ 25 and NIHSS \> 5,Glasgow coma score ≥ 8;
* The patients were diagnosed as anterior circulation cerebral infarction and could start remote ischemic postcondioning within 24 hours after onset
* Normal to random time within 24 hours
* Written informed consent signed by patients or their families

Exclusion Criteria

* patients receiving thrombolysis or endovascular therapy;
* modified Rankin scale (mRS) score ≥ 2 before this attack;
* other intracranial lesions, such as cerebral hemorrhage, cerebral venous disease, severe subclavian artery stenosis and other diseases involving the brain;
* Arterial blood pressure ≤ 90/60mmHg or ≥ 180/100mmHg after treatment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Hospital of Xuzhou Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yu Lu, MD

Role: CONTACT

Phone: 0086-18151865060

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XYFY2022-KL026

Identifier Type: -

Identifier Source: org_study_id